Med. praxi. 2022;19(4):279-283 | DOI: 10.36290/med.2022.043

The role of pioglitazon in modern treatment of type 2 diabetes

MUDr. Pavlína Piťhová, Ph.D.

Interní klinika UK 2. LF a FN v Motole, Praha

Type 2 diabetes patients are at high risk for macrovascular complications and suffer from very high cardiovascular mortality. Recent trials have demonstrated that agents in two antidiabetic classes (SGLT2 inhibitors and GLP-1 receptor agonists) are able to reduce cardiovascular complications in diabetics. People have forgotten that very similar evidence is available also in an older preparation - pioglitazone, which can retard the atherosclerotic process and reduce cardiovascular events. Pioglitazone is an insulin sensitizer, that causes durable improvement of metabolic control and improves multiple components of metabolic syndrome including non-alcoholic fatty liver disease. Treatment with pioglitazone is accompanied by some adverse effects but is still usable in the treatment schema in type 2 diabetic patients.

Keywords: type 2 diabetes, insulin resistence, insulin sensitizers, pioglitazone.

Published: September 29, 2022  Show citation